Scilex, Vera Therapeutics rise premarket; Strategy gains

U.S. stock index futures edged higher on Monday, with Nasdaq 100 futures up 1.1% as investors returned from the holiday weekend. Notable premarket movers included Scilex Holding +7% after a proposed $100M strategic investment term sheet and Solaris Energy Infrastructure +3.9% after Wolfe Research started with an Outperform rating and a $120 target, alongside an acquisition for about $55M. Strategy gained 3.4% after adopting a Digital Credit Capital Framework that can selectively monetize up to $1.25B of Bitcoin holdings to bolster liquidity, fund preferred dividends, and support share repurchases, while Vera Therapeutics rose 6% ahead of its July 7 PDUFA decision.

Analysis

SCLX is a financing trade first and a fundamental trade second. A strategic check can re-rate the stock for a few sessions, but unless the round meaningfully extends runway, the market is still underwriting dilution rather than product value; that means the next move depends on deal terms, not the headline. If the capital comes in at a steep discount or with heavy warrants, the rally should fade once the squeeze is digested.

VERA is the cleanest binary. Into PDUFA, implied volatility usually prices a better-than-even outcome, so the real question is not approval versus rejection but whether the FDA gives a commercially useful label and a fast path to uptake; a narrow green light can still be a sell-the-news event. The contrarian risk is a delay or CMC-related pushout, which would reset the timeline by months and likely compress the multiple hard.

SEI looks more interesting on a 1-3 month horizon than today’s premarket move suggests. The acquisition and coverage initiation can support a rerating if the market starts capitalizing recurring service revenue as a higher-quality cash flow stream in a power-constrained environment, but the thesis breaks if integration drags or customer concentration proves higher than expected. Strategy’s liquidity framework also matters: it lowers forced-selling risk in the near term, but it changes the equity story from pure BTC beta to managed monetization, which should cap upside convexity versus spot Bitcoin.

Key Decisions for Investors

• VERA: stay light or flat into the July 7 decision unless you are explicitly trading the event. If already long, hedge with short-dated puts or a call spread; the trade is wrong if FDA delivers a clean approval plus clear commercial launch language.
• SCLX: do not chase the gap until the financing terms are public. Buy only if dilution is modest and runway meaningfully extends; otherwise fade strength with a small short or put spread because this remains a capital-structure story.
• SEI: tactical long for 1-3 months on any pullback, with the thesis that the market will reward a consolidator in power infrastructure. Falsify the trade if the stock gives back the gap after deal details and management signals the acquired revenue is not recurring enough to justify a higher multiple.
• Strategy: if BTC volatility re-accelerates, prefer long Strategy preferred/capital-structure exposure versus the common, or short the common against BTC spot. The framework reduces tail-risk dilution and forced selling, but it also limits upside convexity in a sharp BTC rally.